Flower D.R.,Aston University |
Phadwal K.,Oxford Biomedical Research Center |
MacDonald I.K.,Oncimmune |
Coveney P.V.,University College London |
And 2 more authors.
Immunome Research | Year: 2010
Atomistic Molecular Dynamics provides powerful and flexible tools for the prediction and analysis of molecular and macromolecular systems. Specifically, it provides a means by which we can measure theoretically that which cannot be measured experimentally: the dynamic time-evolution of complex systems comprising atoms and molecules. It is particularly suitable for the simulation and analysis of the otherwise inaccessible details of MHC-peptide interaction and, on a larger scale, the simulation of the immune synapse. Progress has been relatively tentative yet the emergence of truly high-performance computing and the development of coarse-grained simulation now offers us the hope of accurately predicting thermodynamic parameters and of simulating not merely a handful of proteins but larger, longer simulations comprising thousands of protein molecules and the cellular scale structures they form. We exemplify this within the context of immunoinformatics. © 2010 Flower et al. Source
Bailey G.D.,Oncimmune |
Hyun J.-K.,Korea Basic Science Institute |
Mitra A.K.,University of Auckland |
Kingston R.L.,University of Auckland
Journal of Molecular Biology | Year: 2012
The genome of a retrovirus is surrounded by a convex protein shell, or capsid, that helps facilitate infection. The major part of the capsid surface is formed by interlocking capsid protein (CA) hexamers. We report electron and X-ray crystallographic analysis of a variety of specimens assembled in vitro from Rous sarcoma virus (RSV) CA. These specimens all contain CA hexamers arranged in planar layers, modeling the authentic capsid surface. The specimens differ only in the number of layers incorporated and in the disposition of each layer with respect to its neighbor. The body of each hexamer, formed by the N-terminal domain of CA, is connected to neighboring hexamers through C-terminal domain dimerization. The resulting layer structure is very malleable due to inter-domain flexibility. A helix-capping hydrogen bond between the two domains of RSV CA creates a pivot point, which is central to controlling their relative movement. A similar mechanism for the governance of inter-domain motion was recently described for the human immunodeficiency virus type 1 (HIV-1) capsid, although there is negligible sequence identity between RSV and HIV-1 CA in the region of contact, and the amino acids involved in creating the pivot are not conserved. Our observations allow development of a physically realistic model for the way neighboring hexamers can tilt out of plane, deforming the hexamer layer and generating the continuously curved surfaces that are a feature of all retroviral capsids. © 2012 Elsevier Ltd. Source
News Article | September 14, 2015
Oncimmune, a leader in early cancer detection, today announced the appointment of Meinhard Schmidt as Non-Executive Chairman. Meinhard has more than 25 years international experience as an entrepreneur and senior executive in the diagnostics and medical devices industries. Between 1998 and 2008 he was at Roche Diagnostics where he held various global senior leadership roles and was global Senior VP at Lab Diagnostics, which achieved the leading global position in the laboratory industry. Meinhard has strong board level experience and has worked across M&A, global operations, sales and marketing, program and innovation management and has held executive management positions in Germany, The Netherlands, USA, Canada, Sweden, UK and Switzerland. He currently serves as Board Director at Sphere Medical PLC, valuationLAB AG, CeQur AG and as Chairman at Promimic AB. Meinhard Schmidt, said: "The early detection of cancer can transform outcomes for patients. Oncimmune's EarlyCDT® technology has an excellent scientific pedigree, has been extensively validated and EarlyCDT®-Lung is already on the market in the US, UK and other territories. With the prospect of building on the technology platform to expand into additional cancer types and reach new markets, Oncimmune is poised for growth and I'm very pleased to become Chairman at this exciting time in the Company's development." Geoffrey Hamilton-Fairley, CEO of Oncimmune Limited, said: "It is a great pleasure to welcome Meinhard as Chairman of Oncimmune. His industry experience is exceptional and I very much look forward to working with him as we accelerate the next stage in the Company's development, namely the further commercialisation of EarlyCDT®-Lung on a global basis and the launch of our new EarlyCDT® cancer tests. Meinhard's commercial expertise will enable us to realise the potential of our pioneering autoantibody approach to cancer detection." EarlyCDT-Lung is being used in the world's largest randomised trial for the early detection of lung cancer using biomarkers ever conducted; the National Health Service (NHS) Scotland ECLS study of more than 10,000 high-risk smokers. Early results showing a cancer detection rate of 81%, better than the stated test performance, were recently presented at the 16th World Conference on Lung Cancer. Oncimmune is an industry leader in early cancer detection. The company has pioneered the development of autoantibody assay technologies that have the potential to allow earlier cancer detection than other methods and be applied to a very wide range of solid tumour types. The Company's proprietary EarlyCDT® technology platform was launched in 2009 and EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT® tests for liver and ovarian cancer are in final validation. Oncimmune is headquartered in Nottingham, United Kingdom with testing facilities in the US.
News Article | June 2, 2010
The detection and treatment of solid cancers such as lung, breast, ovarian, colon, and prostate cancers could be on the verge of a major makeover, thanks to a new blood test developed at the University of Nottingham and spinoff company Oncimmune. Early in a tumor's development, cancer cells produce antigens that trigger the body's immune system to release auto-antibodies in an attempt to fight them off. The body produces an abundance of these auto-antibodies to win the battle--more than the tumor does antigens, making the auto-antibodies easier to detect. The test measures a panel of auto-antibodies in a blood sample to determine the likelihood of a tumor being present. In clinical trials, it has helped detect cancer as many as five years earlier than current mammography and CT scans. Based on the early work of John Robertson, a renowned breast cancer specialist and University of Nottingham professor who launched Oncimmune in 2003, the company's first blood test to hit the market--called EarlyCDT-Lung--is to be released in the U.S. later this month and in the U.K. in early 2011. "We believe this test, along with the others we will launch in the next few years, will lead to a better prognosis for a significant number of cancer sufferers," says Geoffrey Hamilton-Fairley, Oncimmune's executive chairman, in a news release. The research first launched at Nottingham analyzed blood samples from patients with breast cancer and a group of high-risk women in for an annual mammography. Robertson identified not only the signal in the blood of those women who developed breast cancer, but he also found that his prototype test could have detected cancer in more than half the patients up to four years before they were eventually diagnosed. The more recent research resulting in the lung cancer test came out of a European Union grant involving the university and Oncimmune. The EarlyCDT-Lung test's target population is high-risk individuals, from long-term and ex-smokers over the age of 40 to people exposed to radon, asbestos, or extensive second-hand smoke. Oncimmune says EarlyCDT-Lung will be available in the U.S. via primary care physicians and pulmonologists, and the company will bill private insurance companies as well as government-run Medicare Part B carriers on behalf of the patient. "I am very pleased that the initial exciting research data that we produced in the laboratories at the University of Nottingham a number of years ago have been translated by Oncimmune to the first of many tests that will help us identify cancer early," Robertson said. "It has been a long and at times very hard road in creating a robust commercial test."
Oncimmune | Date: 2013-09-24
The application generally relates to the field of diagnostic or prognostic assays and in particular relates to assays for the detection of antibodies in a sample comprising patient bodily fluid, wherein such antibodies are used as biological markers of a disease state or disease susceptibility. The assay is based on cross-titration of both the patient bodily fluid to be tested for the antibody and an antigen used to detect the antibody by specific binding.